Skip to main content

Health condition

Peripheral nerve tumours, from a harmless lump to a suspected sarcoma pathway.

Most growths arising from a nerve or its supporting tissue are benign and slow-growing. A minority are malignant - knowing the difference in features is what this guide covers.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG161 and peer-reviewed sarcoma and peripheral nerve literature you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK pathways for suspected sarcoma, including specialist MDT referral routes.

Key facts

Peripheral nerve tumours at a glance.

The essentials, in plain English - what they are, why most are harmless, and how the minority that aren’t are found.

  • What it is

    Growths arising from a peripheral nerve or the cells that support it - Schwann cells, perineural cells or fibroblasts.

  • Mostly benign

    Schwannomas and neurofibromas make up the great majority - see our dedicated benign guide for detail on these.

  • A minority are malignant

    Malignant peripheral nerve sheath tumours (MPNST) are rare but carry a high recurrence risk if not caught early.

  • NF1 link

    Neurofibromatosis type 1 sharply raises lifetime MPNST risk - regular surveillance matters for this group.

  • First-line imaging

    MRI characterises the lesion and plans any biopsy - the standard first step under NICE NG161.

  • Specialist pathway

    Concerning lesions go to a commissioned sarcoma centre with neurosurgery and genetics input.

Why this guide matters

Telling benign from malignant, early.

Peripheral nerve tumours span a wide range from a harmless lump to a rare but serious sarcoma. The three points below shape everything else on this page.

  • Most lesions are entirely benign

    Schwannomas and solitary neurofibromas rarely need anything more than excision if symptomatic, or simple observation. Our benign peripheral nerve tumours guide covers this group in depth.

  • A change in behaviour is the signal

    Pain appearing in a painless lump, or rapid growth, is what separates routine follow-up from urgent sarcoma referral.

  • NF1 changes the risk calculation

    People with neurofibromatosis type 1 carry a lifetime MPNST risk that justifies regular specialist surveillance.

The spectrum

One family of lumps, four very different tumours.

Peripheral nerve tumours are best understood as a spectrum. This page is the hub; the links below take you deeper into each type.

  • Schwannoma

    A benign tumour of Schwann cells, usually solitary, slow-growing and encapsulated - it can often be shelled out from the nerve with function preserved. See our nerve sheath tumours guide for detail.

  • Neurofibroma

    A benign tumour intermixed with the nerve fibres themselves, either solitary or, in neurofibromatosis type 1, occurring in large numbers across the body. See our dedicated neurofibroma guide.

  • Plexiform neurofibroma

    A larger, more diffuse benign form seen in NF1 that can involve multiple nerve branches - the subtype with the highest lifetime risk of transforming into MPNST.

  • Malignant peripheral nerve sheath tumour (MPNST)

    A rare, aggressive sarcoma arising from a nerve or, more often, from an existing neurofibroma - the reason this hub exists alongside the benign-only guide.

Deeper dive

Benign peripheral nerve tumours in full

Related guide

Nerve sheath tumours (schwannoma focus)

How the diagnosis is made

From first lump to a clear plan.

The steps a UK clinician will normally follow under NICE NG161, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and examination

    A palpable lump along a nerve’s course, how quickly it has grown, any pain, and any numbness, tingling or weakness in that nerve’s distribution.

  2. 02

    Assessing

    Tinel’s sign

    Tapping over the lesion reproduces tingling along the nerve - a simple bedside clue that a lump is nerve-related rather than something else.

  3. 03

    Assessing

    MRI as first-line imaging

    MRI characterises size, margins and the lesion’s relationship to the nerve, and is used to plan any biopsy under NICE NG161.

  4. 04

    Confirming

    Core needle biopsy

    Performed at a specialist sarcoma centre for lesions with concerning features - rapid growth, pain, large size, or an NF1 background.

  5. 05

    Confirming

    Genetic assessment

    Where neurofibromatosis type 1 is suspected, genetic assessment clarifies the underlying diagnosis and future risk for the person and their family.

  6. 06

    Preparing

    Specialist sarcoma MDT

    Suspected malignant lesions are discussed at a commissioned sarcoma centre with neurosurgery and genetics represented.

  7. 07

    Preparing

    Treatment planning

    Benign disease is planned for excision if symptomatic or simple observation; malignant disease is planned for wide excision, often with radiotherapy.

Typical timeline: a first scan to a specialist plan within a few weeks.

Symptoms

What a peripheral nerve tumour actually feels like.

A palpable lump along a nerve, with or without sensory or motor change. And the features that mean it’s time to escalate.

  • Palpable lump

    A firm swelling felt along the course of a nerve - the most common first sign, whether the lesion turns out to be benign or malignant.

  • Pain

    Benign lesions are often painless. New or worsening pain in a lump raises concern for malignant change.

  • Rapid growth

    A lump enlarging quickly over weeks, rather than years, is a key feature prompting urgent assessment.

  • Numbness or tingling

    Sensory change in the distribution of the affected nerve, from pressure or infiltration of nerve fibres.

  • Weakness

    Motor weakness in muscles supplied by the nerve suggests more significant nerve involvement.

  • Tinel’s sign

    Tingling on tapping over the lesion, radiating along the nerve - a classic clinical sign of a nerve-related lump.

  • Multiple lesions (NF1)

    Numerous neurofibromas across the body point towards neurofibromatosis type 1 rather than a solitary tumour.

  • Red flag - pain with rapid growth

    Pain plus rapid growth plus a new neurological deficit is the combination that should prompt urgent sarcoma referral.

Treatment

How peripheral nerve tumours are treated in the UK.

Observation or excision for benign disease, and wide excision plus radiotherapy for malignant disease at a specialist sarcoma centre.

  • Observation

    Small, stable, asymptomatic benign lesions are often simply monitored with periodic review rather than operated on.

  • Surgical excision (benign)

    Schwannomas and solitary neurofibromas are excised when symptomatic or when diagnosis is uncertain, aiming to preserve nerve function throughout.

  • Wide surgical excision (MPNST)

    Malignant peripheral nerve sheath tumours need wide excision with clear margins, performed at a specialist sarcoma centre.

  • Radiotherapy

    Often given after resection of MPNST given the high risk of local recurrence, and sometimes used where surgery alone cannot achieve clear margins.

  • Chemotherapy

    Used for advanced or metastatic MPNST, usually as part of a specialist sarcoma protocol alongside surgery and radiotherapy.

  • MDT specialist care

    Sarcoma centre, neurosurgery, plastics and genetics working together for any suspected malignant peripheral nerve tumour.

  • NF1 surveillance

    Regular clinical review, and MRI where indicated, for people with neurofibromatosis type 1, given their lifetime MPNST risk.

  • Genetic counselling

    For confirmed or suspected neurofibromatosis, to explain inheritance patterns and plan appropriate screening for close relatives.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist sarcoma-service standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP or specialist knows your lump and your history and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Suspected sarcoma: recognition and referral (NG161).

  • British Orthopaedic Oncology Society. Guidance on soft-tissue and peripheral nerve tumours.

  • Royal College of Radiologists. Imaging pathways for suspected sarcoma.

  • NHS England. Specialist commissioned sarcoma services.

Red flags

When a peripheral nerve lump needs urgent attention.

Most lumps are benign and can be managed routinely. These are the situations that aren’t - and where a specialist sarcoma opinion is needed.

  • Rapid growth

    A peripheral nerve lump enlarging over weeks, not years, is a leading concern for malignant transformation.

  • New pain in a previously painless lump

    Pain developing in a lesion that was previously painless suggests possible malignant change and needs prompt review.

  • Progressive neurological deficit

    New or worsening weakness, numbness or loss of function in the nerve’s distribution warrants urgent specialist assessment.

  • Large size at presentation

    Lesions greater than 5cm carry a higher pre-test probability of sarcoma and should be imaged and referred without delay.

  • NF1 background with a changing lesion

    Any neurofibroma that changes in size, pain or texture in a person with NF1 needs urgent sarcoma-pathway assessment.

  • Deep-seated location

    Lesions deep to the fascia are harder to assess clinically and carry a higher relative risk than superficial ones.

  • Fixed or firm consistency

    A lump that feels fixed to surrounding tissue rather than mobile is a feature that raises suspicion.

  • Recurrence after previous excision

    A lesion returning after prior surgery should be reassessed at a specialist sarcoma centre, not simply re-excised locally.

  • Delayed access to a sarcoma MDT

    Any suspected malignant peripheral nerve tumour should reach specialist sarcoma and neurosurgery input without unnecessary delay.

Living with it

A watchful, well-informed approach, not constant worry.

Four things that make the biggest difference day to day - knowing your baseline, reporting change promptly, keeping surveillance if you have NF1, and understanding your genetics.

A quiet reminder

Change, not size alone, is what matters most.

A lump that has looked the same for years is reassuring. It is new pain, new growth or new nerve symptoms that deserve attention.

  1. 01 Monitor

    Know your own baseline

    Note the size, shape and feel of a known lesion so you can recognise genuine change early.

  2. 02 Report

    Flag pain or growth promptly

    New pain, faster growth or new numbness or weakness should be reported rather than watched at home.

  3. 03 NF1 care

    Keep up annual surveillance

    If you have neurofibromatosis type 1, regular specialist review is the main way MPNST is caught early.

  4. 04 Support

    Ask about genetics and family risk

    Genetic assessment can clarify inheritance patterns and guide screening for close relatives.

Frequently asked

Everything we get asked about peripheral nerve tumours.

Quick answers on diagnosis, the NF1 link, and how benign and malignant disease are treated.

  • What is a peripheral nerve tumour?

    A growth arising from a peripheral nerve or the cells that support it - Schwann cells, perineural cells or fibroblasts. The great majority are benign, such as schwannomas and neurofibromas, but a small minority are malignant peripheral nerve sheath tumours (MPNST).

  • What is the difference between a benign and a malignant peripheral nerve tumour?

    Benign tumours, covered in detail in our benign peripheral nerve tumours guide, are usually slow-growing, painless and stay confined to the nerve they arise from. Malignant tumours (MPNST) tend to grow quickly, can become painful, and may spread beyond the nerve, so they need urgent specialist sarcoma assessment.

  • How is a peripheral nerve tumour diagnosed?

    MRI is used first to characterise the lesion and plan any biopsy. Lesions with concerning features - rapid growth, pain, large size or an NF1 background - go on to core needle biopsy at a specialist sarcoma centre.

  • Are these tumours linked to neurofibromatosis?

    Yes. People with neurofibromatosis type 1 have a markedly increased lifetime risk of MPNST developing within an existing neurofibroma, which is why regular surveillance matters for this group.

  • What symptoms suggest malignant change in a peripheral nerve tumour?

    Pain in a previously painless lump, rapid growth, and new numbness, tingling or weakness in the nerve’s distribution are the features that should prompt urgent specialist assessment.

  • How are peripheral nerve tumours treated?

    Benign lesions are excised if symptomatic or if the diagnosis is uncertain, or simply observed if stable. Malignant peripheral nerve sheath tumours need wide surgical excision at a specialist sarcoma centre, often combined with radiotherapy, with chemotherapy reserved for advanced or metastatic disease.

Related content

Keep reading.